1-13 of 13
Emiliano Calvo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Unveiling the Mechanism of Lurbinectedin’s Action and Its Potential in Combination Therapies in Small Cell Lung Cancer

Antonio Calles, Emiliano Calvo, Gema Santamaría Nuñez, Federico Costanzo, María José Guillén, Marta Martinez Diez, Aparna Gupta, Carmen Cuevas, Jean-Marc Egly, Pablo Avilés
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther OF1–OF12.
https://doi.org/10.1158/1535-7163.MCT-24-0050
Published: 30 December 2024
View article titled, Unveiling the Mechanism of Lurbinectedin’s Action and Its Potential in Combination Therapies in Small Cell Lung Cancer
Open the PDF for Unveiling the Mechanism of Lurbinectedin’s Action and Its Potential in Combination Therapies in Small Cell Lung Cancer in another window
Journal Articles

Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study

Funda Meric-Bernstam, Emiliano Calvo, Keun Seok Lee, Victor Moreno, Yeon Hee Park, Sun Young Rha, Pavani Chalasani, Wei Zhong, Li Zhou, Steven Pirie-Shepherd, Abraham C.F. Leung, Giuseppe Curigliano
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (10): 1191–1203.
https://doi.org/10.1158/1535-7163.MCT-23-0101
Published: 02 October 2023
View article titled, Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Open the PDF for Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study in another window
Includes: Supplementary data
Journal Articles

Abstract P06-01: A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced stage solid tumors (Acronym: GDFATHER)

Ignacio Melero, Emiliano Calvo, Maria-Elisabeth Goebeler, Elena Garralda, Reinhard Dummer, María Rodríguez-Ruiz, María De Miguel, Cyrus Sayehli, Guzman Alonso Casal, Egle Ramelyte, Martin Schuler, Tanja Gromke, Miguel Sanmamed, Irene Moreno, Ralf Bargou, Maria Lostes, Julia-Tatjana Maul, Heike Richly, Petra Fettes, Kathrin Klar, Christine Schuberth-Wagner, Markus Haake, Joerg Wischhusen, Eugen Leo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P06-01.
https://doi.org/10.1158/1535-7163.TARG-21-P06-01
Published: 01 December 2021
View article titled, Abstract P06-01: A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced stage solid tumors (Acronym: GDFATHER)
Journal Articles

Abstract P033: CC-95775, a reversible, oral bromodomain and extra-terminal (BET) inhibitor in patients with advanced solid tumors (STs): Results of a phase 1 study

Thierry Lesimple, María José de Miguel, Cristophe Le Tourneau, Mariano Ponz-Sarvise, Marie Paule Sablin, Diego Salas Benito, Bishoy Hanna, Henry Chang, Xin Wei, Marta Ocejo Garcia, Pilar Lardelli, Tania Sánchez, Josep Lluís Parra Palau, Zariana Nikolova, Emiliano Calvo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P033.
https://doi.org/10.1158/1535-7163.TARG-21-P033
Published: 01 December 2021
View article titled, Abstract P033: CC-95775, a reversible, oral bromodomain and extra-terminal (BET) inhibitor in patients with advanced solid tumors (STs): Results of a phase 1 study
Journal Articles

Abstract A092: Phase 1 trial of RO6874813, a novel bispecific FAP-DR5 antibody, in patients with solid tumors

Johanna Bendell, Jean-Yves Blay, Philippe Cassier, Todd Bauer, Catherine Terret, Claudia Mueller, Anthony Morel, Evelyne Chesne, Zhi-xin Xu, Jean Tessier, Maurizio Ceppi, Ian James, Sabine Wilson, Elizabeth Quackenbush, Maria Ochoa de Olza, Josep Tabernero, Maria De Miguel, Emiliano Calvo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A092.
https://doi.org/10.1158/1535-7163.TARG-17-A092
Published: 01 January 2018
View article titled, Abstract A092: Phase 1 trial of RO6874813, a novel bispecific FAP-DR5 antibody, in patients with solid tumors
Journal Articles

Abstract A028: Biomarker analysis in a phase 1 study of the antibody-drug conjugate ABBV-221 in patients with solid tumors likely to overexpress the epidermal growth factor receptor (EGFR)

Emiliano Calvo, James M. Cleary, Victor Moreno, Maryella Gifford, Lisa Roberts-Rapp, Peter J. Ansell, Ho-Jin Lee, Beibei Hu, David Barch, Christopher Ocampo, Anthony W. Tolcher
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A028.
https://doi.org/10.1158/1535-7163.TARG-17-A028
Published: 01 January 2018
View article titled, Abstract A028: Biomarker analysis in a phase 1 study of the antibody-drug conjugate ABBV-221 in patients with solid tumors likely to overexpress the epidermal growth factor receptor (EGFR)
Journal Articles

Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors

Anthony W. Tolcher, Wei Peng, Emiliano Calvo
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2018) 17 (1): 3–16.
https://doi.org/10.1158/1535-7163.MCT-17-0349
Published: 01 January 2018
View article titled, Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors
Open the PDF for Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors in another window
Journal Articles

Abstract A73: A Phase I first-in-human (FIH) study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs) (NCT01156870).

Valentina Boni, Olivier Rixe, Drew Rasco, Carlos Gomez-Roca, Emiliano Calvo, John C. Morris, Anthony W. Tolcher, Sylvie Assadourian, Helene Guillemin, Jean-Pierre Delord
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A73.
https://doi.org/10.1158/1535-7163.TARG-13-A73
Published: 01 November 2013
View article titled, Abstract A73: A Phase I first-in-human (FIH) study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs) (NCT01156870).
Journal Articles

Abstract C65: Overcoming docetaxel resistance through m-TOR inhibition: A phase I study of the combination of docetaxel and temsirolimus.

Ignacio Duran, Clara Montagut, Emiliano Calvo, Alicia Navarrete, Antonia Garcia, Manuel Hidalgo, Jesus Rodriguez-Pascual, Antonio Cubillo, Coral Barbas, Juan F. Rodriguez-Moreno, Lorena Sanchez, Susana Galtes, Belen Valenzuela, Andrea Viqueira, Joaquin Bellmunt
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C65.
https://doi.org/10.1158/1535-7163.TARG-11-C65
Published: 12 November 2011
View article titled, Abstract C65: Overcoming docetaxel resistance through m-TOR inhibition: A phase I study of the combination of docetaxel and temsirolimus.
Journal Articles

Abstract A91: A phase I dose-escalation study of bosutinib plus capecitabine in selected advanced solid tumors.

Steven Isakoff, Ding Wang, Mario Campone, Antonio Calles, Nathalie Bardy-Bouxin, Ladan Duvillie, Emiliano Calvo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A91.
https://doi.org/10.1158/1535-7163.TARG-11-A91
Published: 12 November 2011
View article titled, Abstract A91: A phase I dose-escalation study of bosutinib plus capecitabine in selected advanced solid tumors.
Journal Articles

Abstract A94: Dose determination of LY2603618, a Chk1 inhibitor, administered in combination with gemcitabine in patients with advanced cancer.

Emiliano Calvo, Donald Richards, Fadi Braiteh, Daniel Von Hoff, Robert McWilliams, Carlos Becerra, Matthew Galsky, Gayle Jameson, Karla C. Hurt, Scott Hynes, Ignacio Garcia-Ribas, Aimee Bence, Eric Westin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A94.
https://doi.org/10.1158/1535-7163.TARG-11-A94
Published: 12 November 2011
View article titled, Abstract A94: Dose determination of LY2603618, a Chk1 inhibitor, administered in combination with gemcitabine in patients with advanced cancer.
Journal Articles

A Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of GTI2040 (GTI), a novel ribonucleotide reductase inhibitor in combination with gemcitabine (Gem) in adult patients (pts) with advanced solid tumors.

Chris Takimoto, Quincy Chu, Yun Yen, Patricia O'Rourke, Joshua Cooper, Sam Pardo, Anthony Tolcher, Amita Patnaik, Kyriakos Papadopoulos, Muralidhar Beeram, Alejandro Ricart, Chia-Chi Lin, Alain Mita, Emiliano Calvo, Igor Espinoza-Delgado, Jamie Zwiebel, John Sarantopoulos
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): C160.
Published: 01 November 2007
View article titled, A Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of GTI2040 (GTI), a novel ribonucleotide reductase inhibitor in combination with gemcitabine (Gem) in adult patients (pts) with advanced solid tumors.
Journal Articles

Targeting aberrant PI3K pathway signaling with XL147, a potent, selective and orally bioavailable PI3K inhibitor

Geoffrey Shapiro, Gerald Edelman, Emiliano Calvo, Sanjay Aggarwal, A. Laird
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): C205.
Published: 01 November 2007
View article titled, Targeting aberrant PI3K pathway signaling with XL147, a potent, selective and orally bioavailable PI3K inhibitor